NASDAQ: AMPH |
| Healthcare / Drug Manufacturers / USA |
34.28 | +2.50 | +7.87% | Vol 368.07K | 1Y Perf 51.91% |
Jun 27th, 2022 16:00 DELAYED |
BID | 31.08 | ASK | 38.75 | ||
Open | 32.22 | Previous Close | 31.78 | ||
Pre-Market | - | After-Market | 34.28 | ||
- - | - -% |
Target Price | 45.00 | Analyst Rating | Moderate Buy 2.00 | |
Potential % | 31.27 | Finscreener Ranking | ★★★+ 51.67 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★+ 54.01 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★★ 67.94 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 62.16 | Earnings Rating | Sell | |
Market Cap | 1.67B | Earnings Date | 8th Aug 2022 | |
Alpha | 0.01 | Standard Deviation | 0.10 | |
Beta | 0.65 |
Today's Price Range 31.9434.69 | 52W Range 17.5644.46 | 5 Year PE Ratio Range -139.30921.10 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 8.45% | ||
1 Month | -11.81% | ||
3 Months | -5.95% | ||
6 Months | 50.09% | ||
1 Year | 51.91% | ||
3 Years | 62.39% | ||
5 Years | 93.89% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 6.12 | |||
ROE last 12 Months | 18.86 | |||
ROA (5Y Avg) | 3.30 | |||
ROA last 12 Months | 12.27 | |||
ROC (5Y Avg) | 3.05 | |||
ROC last 12 Months | 15.49 | |||
Return on invested Capital Q | 4.30 | |||
Return on invested Capital Y | 3.64 | |||
Assets Turnover | 0.70 | |||
Receivables Turnover | 6.70 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
19.60 | ||||
3.24 | ||||
3.68 | ||||
12.70 | ||||
15.50 | ||||
2.50 | ||||
3.52 | ||||
9.82 | ||||
1.47B | ||||
Forward PE | 18.58 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.30 | ||||
3.20 | ||||
0.17 | ||||
0.22 | ||||
95.30 | ||||
Leverage Ratio | 1.50 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
46.30 | ||||
24.00 | ||||
29.90 | ||||
8.00 | ||||
18.37 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
455.12M | ||||
9.32 | ||||
11.44 | ||||
12.28 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | 0.33 | 0.47 | 42.42 |
Q04 2021 | 0.38 | 0.42 | 10.53 |
Q03 2021 | 0.22 | 0.46 | 109.09 |
Q02 2021 | 0.21 | 0.21 | 0.00 |
Q01 2021 | 0.19 | 0.27 | 42.11 |
Q04 2020 | 0.14 | 0.16 | 14.29 |
Q03 2020 | 0.06 | 0.09 | 50.00 |
Q02 2020 | 0.11 | 0.16 | 45.45 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 0.30 | -11.76 | Negative |
9/2022 QR | 0.36 | -14.29 | Negative |
12/2022 FY | 1.46 | -8.75 | Negative |
12/2023 FY | 1.71 | -13.64 | Negative |
Next Report Date | 8th Aug 2022 |
Estimated EPS Next Report | 0.30 |
Estimates Count | 2 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 368.07K |
Shares Outstanding | 48.83K |
Shares Float | 30.84M |
Trades Count | 9.37K |
Dollar Volume | 12.47M |
Avg. Volume | 669.71K |
Avg. Weekly Volume | 559.88K |
Avg. Monthly Volume | 847.57K |
Avg. Quarterly Volume | 601.67K |
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) stock closed at 34.28 per share at the end of the most recent trading day (a 7.87% change compared to the prior day closing price) with a volume of 368.07K shares and market capitalization of 1.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2027 people. Amphastar Pharmaceuticals Inc. CEO is Jack Yongfeng Zhang.
The one-year performance of Amphastar Pharmaceuticals Inc. stock is 51.91%, while year-to-date (YTD) performance is 47.19%. AMPH stock has a five-year performance of 93.89%. Its 52-week range is between 17.56 and 44.46, which gives AMPH stock a 52-week price range ratio of 62.16%
Amphastar Pharmaceuticals Inc. currently has a PE ratio of 19.60, a price-to-book (PB) ratio of 3.24, a price-to-sale (PS) ratio of 3.68, a price to cashflow ratio of 12.70, a PEG ratio of 2.32, a ROA of 12.27%, a ROC of 15.49% and a ROE of 18.86%. The company’s profit margin is 18.37%, its EBITDA margin is 29.90%, and its revenue ttm is $455.12 Million , which makes it $9.32 revenue per share.
Of the last four earnings reports from Amphastar Pharmaceuticals Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.30 for the next earnings report. Amphastar Pharmaceuticals Inc.’s next earnings report date is 08th Aug 2022.
The consensus rating of Wall Street analysts for Amphastar Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $45, which is +31.27% compared to the current price. The earnings rating for Amphastar Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amphastar Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amphastar Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.70, ATR14 : 2.05, CCI20 : -46.09, Chaikin Money Flow : -0.07, MACD : -1.14, Money Flow Index : 40.40, ROC : -23.26, RSI : 43.34, STOCH (14,3) : 22.97, STOCH RSI : 0.51, UO : 43.14, Williams %R : -77.03), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amphastar Pharmaceuticals Inc. in the last 12-months were: Floyd F. Petersen (Option Excercise at a value of $347 179), Floyd F. Petersen (Sold 13 219 shares of value $436 337 ), Howard Lee (Option Excercise at a value of $347 179), Howard Lee (Sold 20 291 shares of value $738 182 ), Jack Yongfeng Zhang (Sold 237 871 shares of value $8 297 123 ), Jacob Liawatidewi (Option Excercise at a value of $545 275), Jacob Liawatidewi (Sold 40 456 shares of value $819 493 ), Michael A. Zasloff (Option Excercise at a value of $347 179), Michael A. Zasloff (Sold 20 291 shares of value $703 569 ), Richard Prins (Option Excercise at a value of $347 179), Richard Prins (Sold 20 291 shares of value $559 314 ), Rong Zhou (Option Excercise at a value of $486 160), Rong Zhou (Sold 61 484 shares of value $1 524 812 ), William J. Peters (Option Excercise at a value of $2 318 597), William J. Peters (Sold 182 836 shares of value $5 178 840 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Strong Buy |
Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable and inhalation products. The business activities are operated through two reportable segments namely finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, naloxone, lidocaine, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API. Its products are used in hospitals or urgent care clinical settings. Geographically the business presence of the firm is seen in the United States and France of which the US accounts for the majority of revenue.
CEO: Jack Yongfeng Zhang
Telephone: +1 909 980-9484
Address: 11570 6th Street, Rancho Cucamonga 91730, CA, US
Number of employees: 2 027
Thu, 09 Jun 2022 18:05 GMT Amphastar Pharmaceuticals (AMPH) Receives a Hold from Needham
- TipRanks. All rights reserved.Fri, 08 Apr 2022 14:45 GMT Amphastar Pharmaceuticals (AMPH) Gets a Hold Rating from Needham
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.